NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding NextCure, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 47 | 49 | +2 |
| Shares | 16.1M | 16.0M | −134.0K (−0.8%) |
| Value | $36.0M | $25.5M | −$10.5M (−29.3%) |
New holders (4)
Institutions that held NextCure, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 36,000 | $57.2K | 0.00% |
| Walleye Capital LLC | 21,247 | $33.8K | 0.00% |
| Jane Street Group, LLC | 19,342 | $30.8K | 0.00% |
| Simplex Trading, LLC | 547 | $0 | 0.00% |
Sold out (2)
Institutions that held NextCure, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Two Sigma Advisers, LP | 57,700 | $128.7K |
| Wells Fargo & Company | 2,157 | $4.81K |